Latest News | USFDA Issues Complete Response Letter for Proposed Biosimilar Insulin Aspart: Biocon
Get latest articles and stories on Latest News at LatestLY. Biotechnology major Biocon on Saturday said the US health regulator has issued a complete response letter for Biocon Biologics' application for Insulin Aspart, a proposed biosimilar for diabetes treatment. Latest News | USFDA Issues Complete Response Letter for Proposed Biosimilar Insulin Aspart: Biocon.